

Claims

1. Use of an antibody specific for CD38 comprising an HCDR1 region of sequence GFTFSSYYMN (SEQ ID NO: 1) or SYYMN (SEQ ID NO: 2), an HCDR2 region of sequence GISGDPSNTYYADSVKG (SEQ ID NO: 3), an HCDR3 of sequence DLPLVYTGFAY (SEQ ID NO: 4), an LCDR1 region of sequence SGDNLRHYVY (SEQ ID NO: 5), an LCDR2 region of sequence GDSKRPS (SEQ ID NO: 6), and an LCDR3 region of sequence QTYTGGASL (SEQ ID NO: 7) in the manufacture of a medicament for the treatment of multiple myeloma, wherein said antibody is to be administered at a dose of 8 mg/kg or more once weekly (q1w) over at least eight weeks.
2. The antibody according to claim 1, wherein said antibody is to be administered at a dose of 16 mg/kg or more.
3. The antibody according to any one of the preceding claims, wherein said antibody is to be administered intravenously.
4. The antibody according to any one of the preceding claims, wherein said antibody is to be administered intravenously over a period of two hours.
5. The antibody according to any one of the preceding claims, wherein said antibody comprises a variable heavy chain of the sequence
QVQLVESGGGLVQPGGSLRLSCAASGFTFSSYYMNWVRQAPGKGLEWVSGISGDPSNTY
YADSVKGRFTISRDN SKNTLYLQMNSLRAEDTAVYYCARDLPLVYTGFAYWGQGTLVTVSS
(SEQ ID NO: 8) and a variable light chain of the sequence
DIELTQPPSVSVAPGQTARISCSGDNLRHYVYVYQQKPGQAPVLVIYGDSKRPSGIPE
RFSGSNSGNTATLTISGTQAEDEADYYCQTYTGGASLVFGGGTKLTVLGQ (SEQ ID NO:
9).
6. The antibody according to any one of the preceding claims, wherein said antibody comprises an IgG1 Fc region.
7. The antibody according to any one of the preceding claims, wherein said antibody is to be administered in combination with dexamethasone.

8. The antibody according to claim 9, wherein said antibody is to be administered in combination with dexamethasone, wherein dexamethasone is dosed at 20mg or 40mg once weekly (q1W).